Depression, Neuroplasticity, and the Role of Psychedelics
- The State of Withdrawal: The psychological and physiological state one enters during the withdrawal phase of addiction, or when the set point has shifted such that previous highs are no longer attainable, is remarkably similar to the symptoms of clinical depression.
- The Image of Children: In studying depression and psychedelics, children are used as a visual metaphor to represent high intensity and a state of wonder, contrasting with the rigidity of the depressed mind.
- Lantern vs. Spotlight Consciousness:
- Spotlight: Represents a state that is very pointed, tightly oriented, and sharply focused—often seen in the negative ruminations of depression.
- Lantern: Represents a state where light is cast everywhere, signifying a broadening of perception and consciousness often induced by psychedelics or seen in the open minds of children.
The Neurobiology of Depression: Critiquing the Monoamine Hypothesis
- The Monoamine Hypothesis Defined: This historically dominant theory posits that depression is a direct result of a deficiency in monoamine neurotransmitters.
- Key Monoamines:
- Serotonin
- Dopamine
- Norepinephrine
- Epinephrine
- The Serendipity Principle: Many findings in psychopharmacology were discovered by coincidence:
- Reserpine: Originally a medication for hypertension. It was found to deplete monoamines, and patients consequently experienced low mood and depression as side effects.
- Tryptophan Depletion Studies: Participants consumed a drink containing all amino acids except tryptophan. This led to a depletion of tryptophan (the precursor to serotonin) in the plasma by up to 80%. In individuals with a history of depression, this depletion significantly worsened their mood.
- Early Antidepressants: Tricyclics and Monoamine Oxidase (MAO) inhibitors were originally developed for other conditions but were found to increase monoamine levels.
- MAO Inhibitors: These block the breakdown of neurotransmitters, acting as an indirect agonist to increase levels of serotonin and dopamine.
- Cigarettes: Natural MAO inhibitors found in cigarettes contribute to an antidepressant-like effect and, by increasing dopamine, make smoking more addictive than nicotine alone.
- Limitations of the Monoamine Hypothesis:
- Temporal Disconnect: SSRIs (Selective Serotonergic Reuptake Inhibitors) increase synaptic serotonin levels within hours, yet clinical relief typically takes 4 to 6 weeks.
- Lack of Replication: Tryptophan depletion studies often failed to replicate in healthy individuals.
- Non-responsiveness: Approximately 30% of patients show no meaningful response to first-line SSRIs, and some never respond to any existing therapy.
Depression as a Whole-System Dysregulation
- The Problem with Single-Neurotransmitter Focus: Emotional dysregulation is not localized to one brain region or one neurotransmitter; it is a whole-body, whole-brain failure of the system.
- The HPA Axis and Cortisol:
- The Hypothalamus-Pituitary-Adrenal (HPA) axis releases cortisol (the stress hormone).
- In a healthy brain, the hippocampus provides negative feedback to check cortisol levels via glucocorticoid receptors.
- In a depressed brain, this feedback loop fails, leading to a chronic, rigid, vicious circle of elevated cortisol.
- Brain Regions and Circuitry:
- Prefrontal Cortex (PFC): Specifically, the ventral medial prefrontal cortex (vmPFC) is critical for emotional regulation.
- Dorsal Raphe Nuclei: Located in the brainstem, this area has the highest density of serotonergic signaling. It coordinates inhibitory (passive) responses.
- Learned Helplessness: A passive state is considered the default response to intense stress. Agency and control must be learned to overcome this.
- Circuit Mechanism: The vmPFC sends signals to GABAergic (inhibitory) neurons. These inhibit the serotonergic signaling in the dorsal raphe, which in turn inhibits passive responses and enables active coping strategies.
- Optogenetics: This state-of-the-art technology allows for the selective stimulation or deactivation of specific neuron populations (e.g., in the PFC or amygdala) using light to study their functions accurately.
Sociological Factors and Prevalence in New Zealand
- Prevalence: Roughly 1 in 6 New Zealanders will experience major depression at least once in their lifetime.
- Demographic Risk Profiles:
- Age: Older populations surprisingly show some of the lowest risk levels.
- Ethnicity: The Māori population is at a significantly higher risk.
- Gender: Females, particularly female parents in two-parent families, show higher rates than the national average.
- Economic Status: Low-income families exhibit poorer mental well-being.
- Vulnerable Groups: Social stigma increases risk for the LGBT community and individuals with disabilities (the latter showing the highest risk levels within their respective age groups).
- Sole Parents: This group is at significantly higher risk for poor mental well-being.
Evolutionary Psychology Perspectives on Depression
- Social Signaling: Depression may serve as a "signal of need" for support. Symptoms like anhedonia (the inability to feel pleasure) and lack of appetite are "costly signals" that are difficult to fake, prompting others to reduce demands or provide help.
- Sickness Behavior: Driven by inflammation, withdrawal may be a way to conserve energy during infection or promote the survival of the kin group by isolating the individual.
- Analytical Rumination: While often negative, repetitive thinking may be an evolved mechanism aimed at analyzing complex social problems, recalibrating behavior after social rejection, or finding better survival strategies.
- The Price of Adaptation: Behavioral traits like hyper-vigilance, while potentially leading to anxiety later in life, may have been adaptive for ancestors living in unstable or violent environments.
Modern Theories: Neuroplasticity and Downstream Effects
- The Neuroplasticity Theory: Clinical action occurs at the downstream level rather than just the synapse.
- BDNF (Brain-Derived Neurotrophic Factor): A neurotrophic factor facilitating neuronal growth and connectivity.
- Molecular Cascade:
- BDNF binds to TRAC B receptors.
- This triggers a cascade of molecular actions.
- Results in neuron proliferation, improved survival, and increased dendritic branching/spines.
- Restores hippocampal function and improves mood.
- Atrophy and Inflammation: Stress and trauma cause dendritic branches to atrophy, leaving fewer spines and connections. This is often accompanied by increased inflammatory markers. People with chronic inflammation (e.g., gum disease) show higher incidences of depressive symptoms.
The Psychedelic Renaissance and Mechanisms of Action
- Defining Psychedelics: A class of psychoactive compounds (LSD, Psilocybin, DMT, Mescaline) that produce profound changes in perception, cognition, and the sense of self (ego dissolution).
- Pharmacological Targets:
- Classical psychedelics act as selective agonists for the 5−HT2A receptor.
- These receptors are found in high density on pyramidal neurons, particularly in the prefrontal cortex.
- Ketanserin: A 5−HT2A antagonist that completely blocks the hallucinogenic effect of psychedelics.
- Cellular Mechanisms:
- Psychoplastogens: Psychedelics are described as psychoplastogens because they rapidly increase dendritic spine density (observed within 24 hours in mice).
- Neurogenesis: Research in rodents and planaria worms suggests psychedelics may promote the growth of new neurons in the hippocampus.
- Anti-inflammatory: Signaling through 5−HT2A has been shown to reduce pro-inflammatory cytokines.
- Computational Mechanism (Predictive Coding):
- Reality is constructed in the brain based on "priors" (previous beliefs/expectations).
- Depression is characterized by pathologically rigid priors (e.g., "I am a failure," "Nothing will change").
- Psychedelics temporarily loosen these rigid priors, relaxing the brain's focus and allowing for "lantern consciousness."
- Connectivity: Under psychedelics, communication between brain regions that normally do not interact increases, leading to experiences like synesthesia (e.g., seeing music).
History and Clinical Application of Psychedelics
- Historical Figures:
- Albert Hoffman (1940s): Synthesized LSD at Sandoz. Accidental absorption led to the famous "Bicycle Day" self-experiment with a massive dose of 250μg.
- Aldous Huxley: Author of The Doors of Perception, describing his experience with mescaline from peyote cacti.
- Humphrey Osmond: The psychiatrist who coined the term "psychedelic" (meaning "mind-manifesting").
- Timothy Leary and Richard Alpert: Harvard professors who conducted mushroom research in the 1960s before being fired for questionable methods. Alpert later became known as Ram Dass.
- Criminalization: In the late 1960s and early 1970s, the Nixon government's Controlled Substance Act classified psychedelics as Schedule 1 (no acceptable medical use), halting research for 30 years.
- Clinical Efficacy (Modern Trials):
- Terminal Cancer Patients: Trials at institutions like Johns Hopkins found that a single dose of psilocybin significantly reduced the fear of death and despair, with effects lasting up to 4 years in some cases.
- Standardized Context: Trials involve two therapists, music (e.g., the Johns Hopkins Psychedelic Playlist), and a comfortable, supportive setting.
- The MDMA Setback: Despite its promise for PTSD, the FDA rejected MDMA-assisted therapy applications two years ago. Rejection criteria included "functional blinding" issues (participants usually know if they received the drug) and concerns regarding therapist conduct.
The Importance of Set, Setting, and Integration
- Vulnerability: Because psychedelics open a "window" of neuroplasticity, the environment and mindset during the experience are critical.
- Set: The internal mindset and intentions of the individual.
- Setting: The physical surroundings and the presence of supportive individuals or therapists.
- Integration: The process of making sense of the psychedelic experience and incorporating it into future behavior, often aided by community or traditional ceremonies.